Inventor · disambiguated record
Peter Kiener
Also filed as: KIENER PETER · KIENER PETER A
22 granted patents·40 pending applications·1,839 citations·filing 1989–2024
97Inventor score
Top patents by PatentIndex Score
62 records- 0199US7658921B2Molecules with extended half-lives, compositions and uses thereofMEDIMMUNE LLC·Filed 2007·Granted Feb 9, 2010·185 cites·14 claims
- 0299US5977318ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Nov 2, 1999·438 cites·4 claims
- 0398US5122368AAnthracycline conjugates having a novel linker and methods for their productionBRISTOL MYERS SQUIBB CO·Filed 1989·Granted Jun 16, 1992·605 cites·12 claims
- 0497US5968510ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1996·Granted Oct 19, 1999·157 cites·1 claims
- 0596US5851795ASoluble CTLA4 molecules and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1995·Granted Dec 22, 1998·182 cites·21 claims
- 0695US9988459B2Anti-IFNAR1 antibodies with reduced Fc ligand affinityMEDIMMUNE LLC·Filed 2017·Granted Jun 5, 2018·21 cites·2 claims
- 0793US8323653B2Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseDAMSCHRODER MELISSA·Filed 2007·Granted Dec 4, 2012·32 cites·9 claims
- 0893US5885579ACTLA4 receptor and uses thereofBRISTOL MYERS SQUIBB CO·Filed 1997·Granted Mar 23, 1999·122 cites·11 claims
- 0992US8883992B2Humanized anti-CD19 antibodiesMEDIMMUNE LLC·Filed 2012·Granted Nov 11, 2014·11 cites·9 claims
- 1092US7585504B2High affinity antibodies against HMGB1 and methods of use thereofMEDIMMUNE LLC·Filed 2005·Granted Sep 8, 2009·21 cites·16 claims
- 1188US8137670B2Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cellsWU HERREN·Filed 2006·Granted Mar 20, 2012·10 cites·20 claims
- 1287US2024417460A1Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseVIELA BIO INC·Filed 2024·Application pending·0 cites
- 1386US9896505B2Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseMEDIMMUNE LLC·Filed 2014·Granted Feb 20, 2018·5 cites·8 claims
- 1486US9676833B2Ang-2-binding modular recognition domain complexes and pharmaceutical compositions thereofZYNGENIA INC·Filed 2014·Granted Jun 13, 2017·6 cites·12 claims
- 1585US10150800B2EGFR-binding modular recognition domainsZYNGENIA INC·Filed 2014·Granted Dec 11, 2018·8 cites·13 claims
- 1685US7964706B2High affinity antibodies against HMGB1 and methods of use thereofMEDIMMUNE LLC·Filed 2006·Granted Jun 21, 2011·10 cites·16 claims
- 1783US2025101116A1Anti-ifnar1 antibodies with reduced fc ligand affinityASTRAZENECA AB·Filed 2023·Application pending·0 cites
- 1882US10301390B2Anti-IFNAR1 antibodies with reduced Fc ligand affinityASTRAZENECA AB·Filed 2018·Granted May 28, 2019·2 cites·3 claims
- 1981US8153131B2High affinity antibodies against HMGB1 and methods of use thereofWU HERREN·Filed 2009·Granted Apr 10, 2012·4 cites·18 claims
- 2081US6455683B1DNA molecules encoding human CLAX proteins and their soluble fusion proteinsBRISTOL MYERS SQUIBB CO·Filed 2000·Granted Sep 24, 2002·13 cites·13 claims
- 2179US8129130B2High affinity antibodies against HMGB1 and methods of use thereofWU HERREN·Filed 2011·Granted Mar 6, 2012·5 cites·4 claims
- 2275US8404236B2Method of identifying membrane Ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cellsWU HERREN·Filed 2012·Granted Mar 26, 2013·2 cites·17 claims
- 2373US2021061906A1Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseVIELA BIO INC·Filed 2020·Application pending·0 cites
- 2473US2020172625A1Anti-ifnar1 antibodies with reduced fc ligand affinityASTRAZENECA AB·Filed 2019·Application pending·0 cites
- 2566US2020055944A1Anti-ifnar1 antibodies with reduced fc ligand affinityASTRAZENECA AB·Filed 2019·Application pending·0 cites
- 2666US2011059078A1Anti-ifnar1 antibodies with reduced fc ligand affinityMEDIMMUNE LLC·Filed 2009·Application pending·0 cites
- 2765US2009148459A1Prevention or Treatment of Cancer Using Integrin alphavbeta3 Antagonists in Combination with Other AgentsWOESSNER RICHARD·Filed 2008·Application pending·0 cites
- 2863US10526381B2Multivalent and monovalent multispecific complexes and their usesZYNGENIA INC·Filed 2017·Granted Jan 7, 2020·0 cites·20 claims
- 2963US2018273621A1Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseVIELA BIO INC·Filed 2018·Application pending·0 cites
- 3062US10087222B2Polynucleotides encoding angiopoietin-2 (ang-2) binding polypeptidesZYNGENIA INC·Filed 2017·Granted Oct 2, 2018·0 cites·19 claims
- 3162US2010143372A1Interferon alpha-induced pharmacodynamic markersMEDIMMUNE LLC·Filed 2007·Application pending·0 cites
- 3262US2015210765A1Multivalent and Monovalent Multispecific Complexes and Their UsesZYNGENIA INC·Filed 2014·Application pending·0 cites
- 3361US2015044222A1Interferon alpha-induced pharmacodynamic markers and uses thereofMEDIMMUNE LLC·Filed 2014·Application pending·0 cites
- 3458US2013259868A1Ang-2 Binding Complexes and Uses ThereofZYNGENIA INC·Filed 2013·Application pending·0 cites
- 3558US2014065142A1Multivalent and Monovalent Multispecific Complexes and Their UsesZYNGENIA INC·Filed 2013·Application pending·0 cites
- 3657US2007166314A1EpA2 monoclonal antibodies and methods of use thereofMEDIMMUNE INC·Filed 2007·Application pending·0 cites
- 3757US2014302058A1Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseasesMEDIMMUNE LLC·Filed 2014·Application pending·0 cites
- 3856US2010278813A1Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodiesMEDIMMUNE INC·Filed 2007·Application pending·0 cites
- 3956US2010261172A1Interferon alpha-induced pharmacodynamic markersMEDIMMUNE LLC·Filed 2008·Application pending·0 cites
- 4056US2017121771A1Interferon alpha-induced pharmacodynamic markers and uses thereofMEDIMMUNE LLC·Filed 2016·Application pending·0 cites
- 4155US2012100166A1Ang-2 Binding Complexes and Uses ThereofROSCHKE VIKTOR·Filed 2011·Application pending·0 cites
- 4255US2009162933A1Epha2 and hyperproliferative cell disordersKIENER PETER A·Filed 2008·Application pending·0 cites
- 4353US2015132313A1Interferon alpha-induced pharmacodynamic markersMEDIMMUNE LLC·Filed 2014·Application pending·0 cites
- 4452US2017101468A1Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseasesMEDIMMUNE LTD·Filed 2016·Application pending·0 cites
- 4551US2015147336A1Interferon alpha-induced pharmacodynamic markers and uses thereofMEDIMMUNE LLC·Filed 2015·Application pending·0 cites
- 4651US2005281783A1Listeria-based EphA2 vaccinesKINCH MICHAEL S·Filed 2004·Application pending·0 cites
- 4751US2004028685A1EphA2 monoclonal antibodies and methods of use thereofFiled 2003·Application pending·0 cites
- 4850US2008305120A1Immunogenic Compositions Comprising Hmgb 1 PolypeptidesMEDIMMUNE INC·Filed 2005·Application pending·0 cites
- 4950US2004096451A1Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodiesFiled 2003·Application pending·0 cites
- 5049US2005175616A1PCDGF receptor antibodies and methods of use thereofFiled 2004·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →